The American Lung Association today announced the launch of the COPD-OMA trial, a national clinical research effort conducted through its Airways Clinical Research Centers (ACRC). The study will ...

Altesa BioSciences, a clinical-stage pharmaceutical company dedicated to improving the lives of people with chronic lung diseases including COPD and asthma, today announced the enrollment of the first ...

Nebuliser use in COPD is highest in severe cases, reflecting worsening symptoms, frequent exacerbations, and the need for ...

Nebulisers are often used reactively, meaning they are introduced when symptoms become difficult to control rather than ...

Nebuliser use in COPD is most common in severe disease with frequent exacerbations, high symptoms, and reduced lung function.

Researchers have found a promising treatment breakthrough for chronic obstructive pulmonary disease (COPD) that avoids many of the drawbacks of current drugs, and it has come from an unexpected place.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The 2026 GOLD report newly highlights disease activity ...

November is National Chronic Obstructive Pulmonary Disease Awareness Month. It’s time to raise awareness about lung disease within our communities. By understanding the causes, reducing our risk ...

As of early 2026, COPD remains the fifth-leading cause of death nationwide and carries a substantial economic burden, with ...

CHICAGO, June 5, 2025 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF)'s, the nation's leading pulmonary fibrosis (PF) research, education, and advocacy organization, invites people living with ...

Recent research suggests that certain biologic medications called monoclonal antibodies may help treat emphysema more effectively than some current therapies. These medications include benralizumab ...